Library
3-MeO-PCP
3-MeO-PCP is a dissociative anesthetic with effects that are compared to PCP and ketamine. It is an NMDA receptor antagonist. It has been available in online research chemical markets since 2010, with wide distribution beginning in 2011. Because it is less physically sedating than ketamine, strong doses of it can cause ambulatory delirious states during which users may not realize they are unable to differentiate reality from fantasy. At least one confirmed death has been associated with its use.
Also known as: 3-meo, 3-Methoxyphencyclidine, 3-OMe-PCP
Classification
- Chemical: Arylcyclohexylamine
- Psychoactive: Dissociative
- Tag: Common
- Tag: Habit-Forming
- Tag: Hallucinogen
- Tag: Research-Chemical
Effects
- Creativity Enhancement
- Increased Heart Rate
- Tactile Disconnection
- Spontaneous Tactile Sensations
- Stimulation
- Physical Euphoria
- Psychosis
- Mania
- Mindfulness
- Depersonalization
- Derealization
- Consciousness Disconnection
- Disinhibition
- Tactile Enhancement
- Tactile Suppression
- Bodily Control Enhancement
- Perception Of Decreased Weight
- Hallucinations
Routes of Administration
Oral
Dosage
- Heavy: 15–18+ mg
- Light: 1 – 5 mg
- Common: 5 – 8 mg
- Strong: 8 – 12 mg
- Threshold: 1.5-3 mg
Duration
- Onset: 0.33-0.67 h
- Comeup: 0.75-2 h
- Peak: 2-3 h
- Offset: 1-2 h
- After Effects: 4-48 h
- Total Duration: 3-5 h
Smoked
Dosage
- Heavy: 25 mg
- Light: 2 – 10 mg
- Common: 10 – 20 mg
- Strong: 20 – 25 mg
- Threshold: 2 mg
Duration
No data available for this section yet.
Insufflated
Dosage
- Heavy: 12–15+ mg
- Light: 1 – 5 mg
- Common: 5 – 8 mg
- Strong: 8 – 12 mg
- Threshold: 1-2 mg
Duration
- Onset: 0.17-0.5 h
- Comeup: 0.75-1.5 h
- Peak: 1.5-2 h
- Offset: 0.75-1 h
- After Effects: 4-48 h
- Total Duration: 2-4 h
Rectal
Dosage
- Heavy: 12 mg
- Light: 1 – 5 mg
- Common: 5 – 8 mg
- Strong: 8 – 12 mg
- Threshold: 1 mg
Duration
- Onset: 0.03-0.17 h
- Comeup: 0.17-0.33 h
- Peak: 0.67-1.5 h
- Offset: 0.5-2 h
- After Effects: 2-48 h
Harm Reduction
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Sources
Substance data is aggregated from the following public harm-reduction and reference sources.
Links
This static page is intended as a readable non-JS and prerender-friendly library export.
